Effect of time of day of recreational and household #physical activity on prostate and breast #cancer risk (MCC‐Spain study)

Experimental evidence indicates that exercise performed at different times of the day may affect circadian rhythms and circadian disruption has been linked to breast and prostate cancer. We examined in a population‐based case‐control study (MCC‐Spain) if the time‐of‐day when physical activity is done affects prostate and breast cancer risk. Lifetime recreational and household physical activity was assessed by in‐person interviews. Information on time‐of‐day of activity … Continue reading Effect of time of day of recreational and household #physical activity on prostate and breast #cancer risk (MCC‐Spain study)

Association of the Implant Surface Texture Used in Reconstruction With #Breast Cancer Recurrence

The potential association between breast implant–related anaplastic large cell lymphoma (BIA-ALCL) and implant texture has raised concerns about the additional unexpected adverse effects of textured implants, including potentially adverse outcomes for other cancers. In addition to the risk of developing BIA-ALCL, breast cancer survivors may worry about whether the type of implant inserted is associated with recurrence of their original cancer—an issue for which little … Continue reading Association of the Implant Surface Texture Used in Reconstruction With #Breast Cancer Recurrence

#Aspirin use and risk of #breast cancer in African American women

Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of breast cancer; however, results of epidemiological studies have been mixed. Few studies have investigated these associations among African American women.. To assess the relation of aspirin use to risk of breast cancer in African American women, we conducted a prospective analysis within the Black Women’s Health … Continue reading #Aspirin use and risk of #breast cancer in African American women

Association of #Menopausal Hormone Therapy With Breast #Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials

In the trial involving 16 608 women with a uterus, 8506 were randomized to receive 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA) and 8102, placebo. In the trial involving 10 739 women with prior hysterectomy, 5310 were randomized to receive 0.625 mg/d of CEE alone and 5429, placebo. The CEE-plus-MPA trial was stopped in 2002 after 5.6 years’ median intervention … Continue reading Association of #Menopausal Hormone Therapy With Breast #Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials

Serum #iodine and #breast cancer risk: A prospective nested case-control study stratified for selenium levels

Iodine has been suggested to protect against breast cancer, but there are no epidemiological studies on individual risk. An interesting finding is that in areas where the exposure to both selenium and iodine are high (e.g. Japan), the risk of breast cancer is lower than in areas where selenium is high and iodine low (e.g. USA), or in areas where both are low (e.g. Northern … Continue reading Serum #iodine and #breast cancer risk: A prospective nested case-control study stratified for selenium levels

Dietary Intake of #Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis

Acrylamide is a probable human carcinogen. Aside from occupational exposures and smoking, diet is the main source of exposure in humans. We performed a systematic review of the association between estimated dietary intake of acrylamide and risk of female breast, endometrial, and ovarian cancers in nonexperimental studies published through February 25, 2020, and conducted a dose–response meta-analysis. We identified 18 papers covering 10 different study … Continue reading Dietary Intake of #Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis

Similar #Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins

To assess whether initiation of insulin glargine (glargine), compared with initiation of neutral protamine Hagedorn (NPH) or insulin detemir (detemir), was associated with an increased risk of breast cancer in women with diabetes.. Ever use of glargine was not associated with an increased risk of breast cancer compared with NPH (HR 0.97; 95% CI 0.88–1.06) or detemir (HR, 0.98; 95% CI 0.92–1.05). No increased risk … Continue reading Similar #Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins

Sustained #weight loss and risk of #breast cancer in women ≥50 years: a pooled analysis of prospective data

..Compared with women with stable weight (± 2kg), women with sustained weight loss had a lower risk of breast cancer. This risk reduction was linear and specific to women not using postmenopausal hormones (>2-4.5kg lost: Hazard Ratio (HR)= 0.82, 95% confidence interval (CI): 0.70-0.96; >4.5-<9kg lost: HR = 0.75, 95% CI: 0.63-0.90; ≥9kg lost: HR = 0.68, 95% CI: 0.50-0.93). Women who lost ≥9kg and gained some (but not … Continue reading Sustained #weight loss and risk of #breast cancer in women ≥50 years: a pooled analysis of prospective data

Use of #anastrozole for #breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial

..3864 women were recruited between Feb 2, 2003, and Jan 31, 2012. 1920 women were randomly assigned to 5 years anastrozole and 1944 to placebo. After a median follow-up of 131 months (IQR 105–156), a 49% reduction in breast cancer was observed for anastrozole (85 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years … Continue reading Use of #anastrozole for #breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial